210 related articles for article (PubMed ID: 19475754)
1. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis.
Putzki N; Fischer J; Gottwald K; Reifschneider G; Ries S; Siever A; Hoffmann F; Käfferlein W; Kausch U; Liedtke M; Kirchmeier J; Gmünd S; Richter A; Schicklmaier P; Niemczyk G; Wernsdörfer C; Hartung HP;
Eur J Neurol; 2009 Jun; 16(6):713-20. PubMed ID: 19475754
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
[TBL] [Abstract][Full Text] [Related]
3. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
4. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.
Jongen PJ; Sindic C; Carton H; Zwanikken C; Lemmens W; Borm G;
J Neurol; 2010 Apr; 257(4):584-9. PubMed ID: 19921303
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study.
Patti F; Pappalardo A; Montanari E; Pesci I; Barletta V; Pozzilli C
J Neurol Sci; 2014 Feb; 337(1-2):180-5. PubMed ID: 24433926
[TBL] [Abstract][Full Text] [Related]
6. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
8. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
[TBL] [Abstract][Full Text] [Related]
11. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Kira J; Ueno Y; Harada N; Hirakata T
Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
[TBL] [Abstract][Full Text] [Related]
13. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
14. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[TBL] [Abstract][Full Text] [Related]
15. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
[TBL] [Abstract][Full Text] [Related]
16. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
17. Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
Arnoldus JH; Killestein J; Pfennings LE; Jelles B; Uitdehaag BM; Polman CH
Mult Scler; 2000 Oct; 6(5):338-42. PubMed ID: 11064444
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
19. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]